FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1982-1984 December 12, 2002 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Podolsky, D. K. PubMed Citation

To the Editor: In his review of inflammatory bowel disease (Aug. 8 issue),¹ Podolsky refers to interleukin-10 as a down-regulatory cytokine, citing findings in murine models. However, recent data do not support an antiinflammatory role for interleukin-10 in patients with inflammatory bowel disease. In this regard, Tilg et al. reported that recombinant interleukin-10 administered to patients with Crohn's disease increased the production of interferon-.² The inflammatory role of interleukin-10 found in their study paralleled the absence of significant benefits in clinical trials assessing the efficacy of high doses of recombinant human interleukin-10.^3,4 Such data reveal the complexity of the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.